Skip to main content

Obesity and the risk of cholangiocarcinoma: a meta-analysis

Tumor Biology volume 35, pages 6831–6838 (2014)Cite this article

Abstract

A number of studies have shown that obesity is implicated in the susceptibility to several cancers. However, the association between obesity and cholangiocarcinoma remains unclear. This meta-analysis aimed to quantitatively assess the association between overweight or obesity and the incidence of cholangiocarcinoma. A literature search was performed for cohort and case-control studies published from 1996 to 2013 using PubMed, Cochrane, and EMBASE databases. Studies were included if they reported odds ratios (ORs) and corresponding 95 % confidence intervals (CIs) of cholangiocarcinoma with respect to obesity or overweight. Normal weight, overweight, and obesity were defined when the body mass index (BMI) was 18.5–24.9, 25–29.9, and ≥30 kg/m2, respectively. Excess body weight was defined as BMI ≥ 25 kg/m2. Ten studies met the inclusion criteria, which included five cohort and five case-control studies. Compared with normal weight, being overweight (pooled OR 1.30, 95 % CI 1.13–1.49), obesity (pooled OR 1.52, 95 % CI 1.13–1.89), and excess body weight (pooled OR 1.37, 95 %CI 1.22–1.55) were significantly associated with cholangiocarcinoma. The funnel plot revealed no evidence for publication bias. Obesity is associated with the increased risk of cholangiocarcinoma, which needs to be confirmed by long-term cohort studies.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 2006;3:33–42.

    Article  PubMed  Google Scholar 

  2. 2.

    Taylor-Robinson SD, Toledano MB, Arora S, et al. Increase in mortality rates for intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut. 2001;48:816–20.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  3. 3.

    Khan SA, Emadossadaty S, Ladep N, et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol. 2012;56:848–54.

    Article  PubMed  Google Scholar 

  4. 4.

    Seyama Y, Makuuchi M. Current surgical treatment for bile duct cancer. World J Gastroenterol. 2007;13:1505–15.

    PubMed Central  Article  PubMed  Google Scholar 

  5. 5.

    Claessen MM, Vleggaar FP, Tytgat KM, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol. 2009;50:158–64.

    Article  PubMed  Google Scholar 

  6. 6.

    Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54:173–84.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  7. 7.

    Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors and pathogenesis of cholangiocarcinoma. HPB. 2008;10:77–82.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  8. 8.

    Adenugba A, Khan SA, Taylor-Robinson SD, et al. Polychlorinated biphenyls in bile of patients with biliary tract cancer. Chemosphere. 2009;76:841–6.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15:556–65.

    PubMed Central  Article  PubMed  Google Scholar 

  10. 10.

    Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer—a dose-response meta-analysis of prospective studies. Ann Oncol. 2012;23:1665–71.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Stroup DF, Berlin JA, Morton SC, Thacker SB, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology Group. JAMA. 2000;283:2008–12.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of non randomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.

    Article  PubMed  Google Scholar 

  13. 13.

    Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1–30.

    CAS  PubMed  Google Scholar 

  14. 14.

    Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.

    Article  Google Scholar 

  15. 15.

    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.

    CAS  PubMed  Google Scholar 

  16. 16.

    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315:629–34.

    CAS  Article  Google Scholar 

  18. 18.

    Wolk A, Gridley G, Svensson M, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Cause Control. 2001;12:13–21.

    CAS  Article  Google Scholar 

  19. 19.

    Samanic C, Gridley G, Chow WH, Lubin J, Hoover RN, Fraumeni Jr JF. Obesity and cancer risk among white and black United States veterans. Cancer Cause Control. 2004;15:35–43.

    Article  Google Scholar 

  20. 20.

    Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol. 2005;23:4742–54.

    Article  PubMed  Google Scholar 

  21. 21.

    Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni Jr JF. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Cause Control. 2006;17:901–9.

    Article  Google Scholar 

  22. 22.

    Ishiguro S, Inoue M, Kurahashi N, Iwasaki M, Sasazuki S, Tsugane S. Risk factors of biliary tract cancer in a large-scale population-based cohort study in Japan (JPHC study); with special focus on cholelithiasis, body mass index, and their effect modification. Cancer Cause Control. 2008;19:33–41.

    Article  Google Scholar 

  23. 23.

    Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007;5:1221–8.

    PubMed Central  Article  PubMed  Google Scholar 

  24. 24.

    Welzel TM, Mellemkjaer L, Gloria G, et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer. 2007;120:638–41.

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Grainge MJ, West J, Solaymani-Dodaran M, Aithal GP, Card TR. The antecedents of biliary cancer: a primary care case-control study in the United Kingdom. Brit J Cancer. 2009;100:178–80.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  26. 26.

    Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54:463–71.

    PubMed Central  Article  PubMed  Google Scholar 

  27. 27.

    Chaiteerakij R, Yang JD, Harmsen WS, et al. Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology. 2013;57:648–55.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  28. 28.

    Eliassen AH, Colditz GA, Rosner B, et al. Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006;296:193–201.

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Dal Maso L, La Vecchia C, Franceschi S, et al. A pooled analysis of thyroid cancer studies. V. Anthropometric factors. Cancer Cause Control. 2000;11:137–44.

    CAS  Article  Google Scholar 

  30. 30.

    Ning Y, Wang L, Giovannucci EL. A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes Rev. 2010;11:19.

    CAS  Article  PubMed  Google Scholar 

  31. 31.

    Somasundar P, Yu AK, Vona-Davis L, McFadden W. Differential effects of leptin on caner in vitro. J Surg Res. 2003;113:50–5.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Cannata D, Fierz Y, Vijayakumar A, LeRoith D. Type 2 diabetes and cancer: what is the connection? Mt Sinai J Med. 2010;77:197–213.

    Article  PubMed  Google Scholar 

  33. 33.

    La Vecchia C. Hypothesis: is the fall in Helicobacter pylori related to the global rise in body mass index? Eur J Cancer Prev. 2011;20:556.

    Article  PubMed  Google Scholar 

  34. 34.

    Clayton PE, Banerjee I, Murray PG, et al. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol. 2011;7:11–24.

    CAS  Article  PubMed  Google Scholar 

  35. 35.

    Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346–53.

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab: TEM. 2006;17:328–36.

    CAS  Article  PubMed  Google Scholar 

  37. 37.

    Renehan AG, Roberts DL, Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem. 2008;114:71–83.

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Vansaun MN. Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res. 2013;19:1926–32.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  39. 39.

    Xue RQ, Gu JC, Du ST, et al. Lentivirus-mediated RNA interference targeting the ObR gene in human breast cancer MCF-7 cells in a nude mouse xenograft model. Chin Med J. 2012;125:1563–70.

    CAS  PubMed  Google Scholar 

  40. 40.

    Yang SN, Chen HT, Tsou HK, et al. Leptin enhances cell migration in human chondrosarcoma cells through OBRl leptin receptor. Carcinogenesis. 2009;30:566–74.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Medjaden Bioscience Limited for assisting in the preparation of this manuscript.

Conflicts of interest

None

Author information

Affiliations

  1. Department of Gastroenterology, Shandong Provincial Hospital, Shandong University, 324 Jing 5 Road, Jinan, 250021, Shandong, China

    Jun-Shan Li, Nie Jing, Xiao-Hua Zhang, Feng-Zhen Ma & Ji-Yong Liu

  2. Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, 250021, Shandong, China

    Tian-Jie Han

  3. Department of Gastroenterology, Tai’an Central Hospital, Tai’an, 271000, Shandong, China

    Lei Li

Authors
  1. Jun-Shan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tian-Jie Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nie Jing
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiao-Hua Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Feng-Zhen Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ji-Yong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ji-Yong Liu.

Additional information

Jun-Shan Li and Tian-Jie Han contributed equally to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Table 1a

(DOCX 21 kb)

Supplementary Table 1b

(DOCX 20 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Li, JS., Han, TJ., Jing, N. et al. Obesity and the risk of cholangiocarcinoma: a meta-analysis. Tumor Biol. 35, 6831–6838 (2014). https://doi.org/10.1007/s13277-014-1939-4

Download citation

Keywords

  • Cholangiocarcinoma
  • Overweight
  • Obesity
  • Overweight
  • Cohort study
  • Case-control study
  • Meta-analysis